Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations

Overview of attention for article published in Journal of Clinical Oncology, October 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog

twitter: 22 X users
guideline: 1 clinical guideline source

Readers on

mendeley: 40 Mendeley

So far, Altmetric has seen 24 X posts from 22 X users, with an upper bound of 126,567 followers.

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibit...: Ingenta Connect - https://t.co/vjHT6LABit #endNF2 #NF2 #NF2Meningioma

@PDBrownOnc FAK inhibitor may work in refractory NF2 mutated ones https://t.co/UV0X0DKRFq

RT @PDBrownOnc: Congrats Drs. Brastianos, Galanis et al 1st genomically driven phase 2 recurrent/progressive #meningioma @Alliance_org A…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 20 additional X posts.